INTRODUCTION
============

Diabetes mellitus (DM) is one of the oldest known human disease currently affecting about 200 million people worldwide \[[@R1]\]. It is estimated that by 2025, more than 300 people globally will have confirmed DM and other 50 million undiagnosed \[[@R2],[@R3]\]. This disease is the most common metabolic disorder in human and it is characterized by hyperglycemia, due to relative or absolute lack of insulin, the insensitivity of insulin or both \[[@R4],[@R5]\]. DM is classified into type 1 or insulin-dependent DM (IDDM) or type 2 or non-insulin dependent DM (NIDDM) or T2DM \[[@R5],[@R6]\]. Type 1 DM represents about 5-10% of all cases of DM whereas T2DM accounts for 90-95% of diabetes. Type 1 DM is characterized mainly by auto-immune-mediated destruction of beta cells of the endocrine pancreas leading to reduced insulin secretion. This form of DM is prevalent in young children \[[@R5],[@R7]\]. On the other hand, T2DM is characterized by insulin resistance and relative insulin deficiency and it is due to sedentary life style, genetic disposition, obesity, human behavior and environmental factors. Both forms of DM can lead to such long-term complications as neuropathy, retinopathy, cardiomyopathy, nephropathy, exocrine gland insufficiency and several other complications and eventually to death \[[@R5]\]. Type 1 DM is treated mainly with insulin whereas T2DM is controlled by hypoglycemic drugs, regular exercise, general change in life style habits and diet including some plant-based food. The plant kingdom is a good potential source for the discovery of novel medicines to treat numerous diseases including DM. Currently, about 400 plants incorporated more than 700 recipes and compounds which have been evaluated extensively for the treatment of diabetes throughout the world \[[@R8]-[@R14]\]. In many parts of the world, especially in poor countries, this may be the only available form of therapy for the treatment of diabetic patients. One such plant is *Momordica charantia*(family name: Cucurbitaceae), nature's own cure for DM. *M. charantia*has been used extensively as an anti-viral, anti-bacterial agent and more so to treat a number of infections and diseases \[[@R13]\]. These include DM, indigestion, fever, skin disease, HIV, viral and bacterial infections, hypertension, reduced cholesterol and inflammation, detoxification of the body, expelling worms from the body, balance certain hormones in the body, enhances immunity, promotes milk flow, prevents different tumors and several other reported medicinal benefits. This review is concerned specifically with the medicinal chemistry of *M. charantia* and its extracts and active constituents to treat DM.

PLANT-BASED ANTI-DIABETIC MEDICINE
==================================

Plant-based medicine has been used cost-effectively worldwide to treat DM. In fact, in many parts of the world, especially poor countries, this may be the only form of therapy available to treat diabetic patients. There are several reviews by different authors about anti-diabetic herbal plants \[[@R9]-[@R11],[@R13],[@R15]-[@R17]\]. One review has listed more than 300 plant species which possess hypoglycemic properties and classified them according to their biochemical names, country of origin, parts used and nature of the active agent(s) \[[@R11]\]. From the current literature, it is evident that *M. charantia* is the most widely used and popular anti-diabetic plant. Thus, this review will concentrate mainly on *M. charantia* and its anti diabetic properties \[[@R13]\].

CHARACTERISTICS OF *M. CHARANTIA*
=================================

Scientific name: Momordica charantia

Kingdom: Plantae

Division: Magnoliophyta

Family: Cucurbetaceae

Genus: Momordica

Species: Charantia

Duration: Annual

Some common names of*M.charantia* include bitter melon, papilla, bitter gourd, salsamino, corrila or karela, hanzal, assorossie, ampalaya, nigauri or goya, pare, kho gua, sora, balsam apple, pear or balsamina, and several other common names (see Taylor, 2002 \[[@R13]\] for extensive review and technical data). *M. charantia* is cultivated in many damp and wet tropical countries of the world including parts of South America and the Amazon basin including Brazil, Guyana and the Caribbean, East Africa and Asia including India, China, Philippines, Pakistan, Nepal and Sri Lanka. *M. charantia* is harvested both as food and as a medicine. It is a slender annual climbing vine with long leaves and at reproductive stage it produces warty or wrinkled gourd green fruits, resembling a squash or a cucumber. *M. charantia* is known for its very bitter taste and this is found in the leaves, the fruits, the stems and other parts of the plant \[[@R17]\]. The bitter taste is a distraction for eating the fruit but this is sometimes overshadowed by its beneficial effect. People normally boil the green leaves and stem and drink the bitter content as tea. Some people cook the fruit as a curry or with meat, while others eat it as a salad, fried it in oil or liquidize it into a herbal juice. In some cases people neutralize the bitter taste with the addition of a fruit (e.g. papaya) or a tropical juice such as mango or with a dash of salt. Commercially, the plant is used to make a powder which is sold commercially as tea or as in capsule form. Medicinally, the plant, its fruit and its powder extract possess a long history of use in the treatment of numerous diseases including diabetes \[[@R9]-[@R11],[@R13],[@R15],[@R17]\].

EXTRACTS AND ACTIVE INGREDIENTS OF *M. CHARANTIA*
=================================================

Generally, the public have used different parts of *M. charantia*including the leaves, the stem and mainly the green fruits or seeds to treat diabetes. Table **[1](#T1){ref-type="table"}** shows the chemical structures of momocharin (**1**) and momordicin (**2**) which is believed to possess insulin-like chemical structure and properties. People eat the fruit raw, boil or cook the different parts or drink the pulp of the fruit as a juice. Over the years several scientists have tried to isolate the various active ingredient of *M. charantia* for commercial purpose.

Fig. (**[1](#F1){ref-type="fig"}**) shows a schematic diagram of the different stages of the isolation procedure for the active ingredient(s) of *M. charantia*fruit employing water and organic solvents. Initially, the fruits are chopped into small pieces and liquidized in deionized water. The green supernatant is separated from the cellulose and subsequently, the water is extracted using a rota-evaporator. The residue is dried in an oven and the green powder extract is used for experimentation or for further extraction, purification and identification employing HPLC, affinity chromatography, SDS-PAGE and NMR mass spectroscopic methods. Two medicinal compounds extracted from *M*. *charantia* include, charantin, a steroidal saponin agent with insulin-like properties and momordicin (**2**), an alkaloid responsible for the bitterness of the fruit \[[@R18]\]. In laboratory and clinical *in vitro*and *in vivo*studies scientists and clinicians have employed different water, ethanol and ether extracts as well as isolated biologically active phytochemicals including glycosides (momordin and charantin), alkaloids (momordicin (**2**)), polypeptide-P, oils from the seeds (linoleic, stearic and oleic acids), glycoproteins (alpha--momorcharin (**1**), beta-momorcharin and lecitins) and others active compounds including protein MAP30 and vicine (pyrimidine nuclease) to study their hypoglycemic properties using both human and animal models \[[@R13]\]. Of these constituents, charantin, insulin-like peptides and alkaloids possess hypoglycemic properties. They are more effective when they are combined and they produce effects almost similar to the crude water soluble extract \[[@R13]\].

COMPOUNDS PRESENT IN *M. CHARANTIA*
===================================

Today around 228 different medicinal compounds have been isolated from the stems, leaves, pericap, entire plant, aerial parts of the plant, endosperm, callus tissues, cotyledons and mainly the seeds and unripe fruit in different laboratories in India, Japan, USA, Thailand, Egypt, China, Taiwan, Australia, Nigeria, Pakistan, Brazil, Nepal, Philippines and Peru \[[@R19]\].

These different compounds have been classified into different chemical types. These includes proteids, triterpenes, lipids, inorganic compounds, phenylpropanoids, carotenoids, steroids, alkaloids, monoterpenes, alkene to C3, carbohydrates, benzanoids, alkanol C5 or more, other unknown structure (e.g. kakara I-B, II-A and III-B) sterol and sesquiterpene. Of the 228 different compounds, most of these fall under the groups of proteids and triterpenes \[[@R13]\].

The plant has many different chemical components, which help medicinally either alone or when combined. One of the hypoglycemic components is a steroid saponin called momocharin (charantin) (**1**) with insulin-like chemical effect. Charantin has a molecular weight of 9.7 kDa and it is the belief that charantin is the active hypoglycaemic agent of *M. charantia*.

Table **[2](#T2){ref-type="table"}** shows similarities in the chemical structures of momocharin (**1**), momordicin (**2**) and other commercially available hypoglycemic drugs (glibenclamide (**3**), gliclazide (**4**), Glipizide (**5**), Metformin hydrochloride (**6**), Pioglitazone hydrochloride (**7**) used in the treatment of T2DM. The hypoglycemic action of *M. charantia* and its isolated components may be due to its insulin-like structure. Recently, two other anti-diabetic constituents were isolated from *M. charantia* and both substances exerted hypoglycemic effects in mice. The cucurbitane triterpenoids were found to have the structures, 5β, 19-epoxycucurbita-6, 5β, 19-epoxy-19, 25-dimethoxycucurbita-6 23-(E)-dien-3β-ol and 3β-7β-25-trihydroxy-cucurbita-5, 23 (E)-dien-19-al. These two compounds have more or less the same parent structure as α-β momocharin (**1**), and momordicin (**2**) \[[@R20]\]. More recently, momordicin 1 (**2**) was isolated from *M. charantia* and its chemical structure was characterized as momordicin1 3, 7, 23,-Trihydroxycucurbitan-5,24-dien-19-al \[[@R20]\]. This compound is more or less similar to the one identifies by Harinantenaina *et al*. \[[@R21]\].

TRADITIONAL REMEDY
==================

The literature has suggested that one-half of one cup of a standard leaves or whole herb concoction, 1-2 times daily is adequate for a hypoglycemic effect. Alternatively, an amount of one to two grams of the water extracted powder from either the leaf or fruit is adequate as a daily dose. Many people liquidize two to three green fruits with water or with a tropical juice and drink 10 to 20 ml twice per day prior to meal. The question which people often ask is: can they take *M. charantia*with traditional commercial anti-diabetic drugs? The answer is to discuss the matter with their General Practitioner first. There may be an element of drug interaction between *M. charantia*and commercially available anti-diabetic glucose lowering drugs but further experiments are required to determine the kind of interaction which may occur between a commercially available hypoglycemic drug and*M. charantia*or its hypoglycaemic extract \[[@R22]\]. For people with T2DM there is no harm in using *M. charantia alone*, but combine this regimen with regular physical exercise and modification of daily diet. Previous studies have described the pharmacology, clinical efficacy, adverse effects, drug interactions and place in therapy of *M. charantia* \[[@R22]\]. It is particularly noteworthy that *M. charantia* is an alternative herbal therapy that has been used primarily to reduce blood glucose level for thousands of years in patients with DM. Regarding adverse effects, some studies have reported hypoglycemic coma and convulsions in children, reduced fertility in mice, a fetish-like syndrome, increase in gamma glutamyltransferase and alkaline phosphatase levels in animals and some headaches \[[@R22]\].

CLINICAL AND BASIC EXPERIMENTAL STUDIES
=======================================

Over the past 50 years, both basic and clinical studies have been done to determine the effect of *M. charantia*on the management of DM. Table **[3](#T3){ref-type="table"}** shows the effect of oral administration of *M. charantia* on both animal and human type 2 models. Today the literature contains over 40 studies employing adult human subjects and another 100 have employed animal models. They were administered with a hot water extract, concoction, the fruit, the fruit juice or the seeds \[[@R13]\]. Typically, of the twenty or more studies present in Table **[3](#T3){ref-type="table"}**, only three have demonstrated no beneficial effects, one on T2DM patient \[[@R16]\], one in rabbit \[[@R23]\] and the other in rat \[[@R24]\]. However, the other seventeen studies have successfully demonstrated that the whole plant, ethanol extract, fruit juice, powder, concoction or seed can evoke hypoglycemic effects. The reason for the three unsuccessful findings may be due to the fact that the authors employed high doses of *M. charantia.*Previous studies have successfully demonstrated that *M. charantia*is more beneficial as a hypoglycemic agent only at therapeutic doses. Either pharmacological or high doses of *M. charantia* seem to exert inhibitory effects \[[@R17],[@R25]\]. To date, not much study have been done on purified components of *M. charantia* in both human and animal models.

POSSIBLE MODES OF ACTION OF *M. CHARANTIA* AND ITS EXTRACT
==========================================================

*M. charantia* and its various extracts and components are believed to exert their hypoglycemic effects via different physiological, pharmacological and biochemical modes \[[@R13],[@R15],[@R17],[@R33]\]. Table **[4](#T4){ref-type="table"}** lists some possible modes of the hypoglycemic actions of *M. charantia* and its various extracts and compounds. Today over 140 different studies worldwide \[[@R13]\] have investigated anti-hyperglycemic and hypoglycemic effects of the different extracts and ingredients of *M. charantia* in both human and animal models. These include the fruit extracts with, either hot water, ethanol, lyophilized, benzene, chloroform, acetone, fruit juice and powder. Of all the different studies, about 120 have reported active and beneficial effects, whereas the remaining 20 have reported inactive or no beneficial effects. There are several reasons for these discrepancies in the activity of *M. charantia*and its various extracts and isolated compounds. These may be due to the duration (short time period) of the experiments, doses of the compounds (high doses seem to evoke inhibitory or toxic effect) \[[@R32]\], the animal models and gender employed in the studies, the method of application/administration, and in some cases the laboratories and countries where the work was done and also the extracts administered. These discrepancies may also be due to seasonal variations \[[@R13]\].

*M. charantia,* its extracts and isolated components are believed to exert their hypoglycaemic effects via different physiological and biochemical processes. These include insulin secretagogue like effect, stimulation of skeletal muscle and peripheral cell glucose utilization, inhibition of intestinal glucose uptake, inhibition of hexokinase activity, suppression of key gluconeogenic enzymes, stimulation of key enzymes, HMP pathway and preservation of pancreatic islet cells and their functions (see Table **[4](#T4){ref-type="table"}** for relevant references).

PRESERVATION OF PANCREATIC β CELLS AND INSULIN SECRETION
========================================================

It was previously demonstrated by Jeewathayaparan *et al.* \[[@R25]\] that oral administration of M.*charantia*could lead to the secretion of insulin from endocrine pancreatic beta cells. This observation was further confirmed by Ahmed *et al*. \[[@R33],[@R39],[@R41]\] who investigated the effect of daily oral administration of *M. charantia* fruit juice and the distribution of α, β and δ cells in the pancreas of streptozotocin (STZ)-induced diabetic rats using immunohistochemical methods. In these studies, they observed that *M. charantia*significantly increased the number of β cells compared to untreated diabetic rats. However, the number of β cells was significantly less than that obtained in normal and*M. charantia-*treated control rats. This may be due to the fact that the study was only done for a period of 10 weeks and moreover, the STZ probably destroyed some of the beta cell completely one week prior to the administration of the fruit juice to the animals. From these studies, the authors concluded that *M. charantia*fruit juice may have a role in the renewal of β cells in treated diabetic rats or alternatively, the juice may permit the recovery of partially destroyed β cells \[[@R33],[@R39],[@R41]\]. Physiological experiments have also shown that *M. charantia*can stimulate insulin secretion from the endocrine pancreas \[[@R42]\] and elicit glucose uptake in the liver \[[@R43]\]. Current evidence therefore indicates that the recovery and subsequent increase in the number of insulin producing cells followed by the release of insulin may be part of the several pathways by which *M. charantia* exerts its hypoglycemic effects. In addition to the properties mentioned above, *M. charantia*and its extracts may possess cell-like proliferation and growth-like properties similar to that of insulin \[[@R5],[@R25]\]. Nevertheless, further experiment are required, at least at the molecular level, to determine the precise mechanisms whereby *M. charantia*can either repair damaged β cells or prevent their death.

*M. CHARANTIA* AND GLUCOSE METABOLISM
=====================================

Insulin plays a major biochemical role in stimulating the uptake of glucose by different cells of the body for the production of energy \[[@R4],[@R5],[@R25]\]. Since *M. charantia* and its various extracts and components have been reported to exert hypoglycemic effects, then it is important to understand whether *M. charantia*may have a direct effect in inducing a reduction in blood glucose level \[[@R13]\]. Previous studies have shown that both the aqueous and alcoholic extracts of the fruit of *M. charantia*can inhibit the activities of fructose 1, 6-diphosphatase and glucose-6-phosphatase and at the same time stimulating the action of glucose-6-phosphatase dehydrogenase \[[@R17],[@R19],[@R34],[@R36]\]. It was previously reported that *M. charantia*and its various extracts can stimulate peripheral cell glucose uptake \[[@R17],[@R19],[@R25]\]. A number of studies have investigated the effect of the powder and chloroform extract of *M. charantia*in comparison with insulin on glucose and amino acid uptakes by skeletal L6 myotubes and Na^+^ and K^+^ glucose uptakes by jejunum brush border membrane vesicles in both age-matched control and STZ-induced diabetic rats. The results show that either the lyophilized fruit juice or chloroform extract at 5-10 μg ml^-1^ can stimulate ^3^H-deoxyglucose and ^14^C--Me AIB (N-methyl-amino-α-isobutyric acid) uptakes by L6 myotubes. These effects were similar in magnitude to the effects obtained with 100 nM insulin. Incubation of either insulin or *M. charantia*juice in the presence of wortmannin (a phosphatidylinositol 3-kinase inhibitor) resulted in a marked inhibition of ^3^H-deoxyglucose uptake by L-6 myotubes \[[@R25],[@R44]\]. Together, the results have clearly demonstrated that *M. charantia*contains insulin like properties, similar to one phytochemical component of *M. charantia* called V-insulin \[[@R13]\].

In addition to its insulin-like effects on skeletal muscle cells, daily oral intake of *M. charantia*fruit juice over a period of 10 weeks significantly reduced the amount of Na^+^ and K^+^-dependent ^14^C-D-glucose absorbed by rat jejunum brush border membrane vesicle compared to vesicles obtained from STZ-induced diabetic rats \[[@R33],[@R41]\]. Taken together, these results clearly demonstrated that *M. charantia* and its extracts can directly regulate blood glucose via two mechanisms. Firstly, it can regulate how much glucose is absorbed by the gut into the blood following a meal and secondly, it can stimulate glucose uptake into skeletal muscle cells just like insulin. Moreover, it seems to exert its effect via the same intracellular signaling pathways as insulin in regulating glucose metabolism in the body \[[@R44]\].

ANTI NEUROPATHIC EFFECT OF *M. CHARANTIA* FRUIT JUICE
=====================================================

Human diabetic neuropathy is both cumbersome and complicated and it may result in severe disability \[[@R5],[@R6]\]. In addition, treatment of diabetic neuropathy is very expensive. The most cost effective way is to either prevent or delay the onset of this, long-term diabetic complication. The influence of *M. charantia*fruit extract and insulin on the ultra-structural abnormalities of myelinated fibers in experimental diabetes in rats was investigated in previous studies \[[@R33],[@R37],[@R40]\].

The results have shown that the mean cross-sectional myelinated fibre area, axonal area and myelin area including the mean maximum myelinated fibres area were significantly less in untreated diabetic rats when compared with age-matched controls. In the *M. charantia*treated diabetic animals, myelinated fibre area and myelin area were significantly greater than untreated diabetics and not significantly different from age-matched controls. The mean value for the maximum fibre area was also significantly greater than untreated diabetics and was not significantly different from age-matched controls. The axon to fibre ratio ('g' ratio) did not differ between any of the experimental groups. It was concluded that the administration of *M. charantia*fruit juice not only reduced blood glucose level but also corrected the structural abnormalities of peripheral nerves in experimental diabetes. These results have strongly indicated that *M. charantia*possesses growth factor-like properties just like insulin \[[@R5],[@R31],[@R37],[@R39]\].

To date, *M. charantia* has been extensively studies worldwide for its medicinal properties to treat a number of diseases \[[@R38]\]. It is described as a versatile plant worthy of treating almost any disease inflicted on mankind. This may be due to the fact the plant possesses over 225 different medicinal constituents \[[@R13]\]. These different compounds may act either separately or together to exert their medicinal effects. In relation to diabetes \[[@R46]\], only charantin, insulin-like peptide and alkaloid-like extracts possess hypoglycemic properties similar to the plant itself or its crude extracts. These different compounds seem to exert their beneficial effects via several mechanisms to control and treat diabetes mellitus.

![Schematic diagram showing the isolation procedures for the active ingredient(s) of M. charantia fruit juice (redrawn from Day *et al* \[[@R19]\]). Further purification and identification procedures employ HPLC, affinity chromatography, SDS-page and mass spectrometry.](TOMCJ-5-70_F1){#F1}
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Chemical Structure of Momorcharin and Momorcidin

  \#        Chemical Structure
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Chemical Structures of Momorcharin (1), Momordicine (2), Glibenclamide (3), Gliclazide (4), Glipizide (5), Metformin Hydrochloride (6), Pioglitazone hydrochloride (7). Note similarities in structure momorcharin and Momordicin and Hypoglycemic agents
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###### 

Effects of Oral Administration of *M. charantia* on Diabetes Mellitus

  Experimental Models                   Parts of Plant used                Effects      References
  ------------------------------------- ---------------------------------- ------------ ---------------------------------------------------------------------------
  Normal and diabetic rats              Whole plant                        Beneficial   Leatherdale *et al*. \[[@R26]\]
  Jeevathayaparan *et al*. \[[@R27]\]                                                   
  Chandrasekar *et al*. \[[@R28]\]                                                      
  Diabetic rats                         Ethanol extract of whole plant     Beneficial   Chandrasekar *et al*. \[[@R29]\]
  Normal and diabetic rats              Fruit juice and various extracts   Beneficial   Ali *et al*. \[[@R30], [@R31]\]
  Human (NIDDM)                         Fruit juice/leaves                 Beneficial   William and Pickup \[[@R6]\]; Ahmad *et al*. \[[@R45]\]
  Human (NIDDM)                         Fruit juice                        No effect    Patel *et al*. \[[@R12]\], Day and Bailey \[[@R8]\]
  Human (NIDDM)                         Fruit powder                       Beneficial   Akhtar *et al*. \[[@R32]\], Ahmed *et al*. \[[@R33]\]
  Normal rabbits                        Fruit juice                        No effect    Kulkarni *et al*. \[[@R23]\]
  Diabetic rabbits                      Fruit juice                        Beneficial   Akhtar *et al*. \[[@R32]\]
  Normal and diabetic rats              Fruit juice                        No effect    Karunanayake *et al*. \[[@R24]\] Platel and Srinivasan \[[@R16], [@R17]\]
  Normal and diabetic rats              Fruit juice                        Beneficial   Srivastavaet *et al*. \[[@R49]\]: Karunanayake *et al*. \[[@R24]\]
  Normal and diabetic rat               Fruit juice                        Beneficial   Sharma *et al*. \[[@R37]\]; Day *et al*. \[[@R19]\]
  Normal and diabetic rats              Seed                               Beneficial   Kedar and Chakrabarti \[[@R35]\]
  Normal and diabetic rats              Fruit juice                        Beneficial   Sharma *et al*. \[[@R34]\]

###### 

Possible modes of hypoglycaemic actions of M. charantia

  Possible Modes of Action   Reference                                                           
  -------------------------- ------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------
  1\.                        Insulin secretagogue effect                                         Karunanayake *et al*. \[[@R24]\], Kedar and Chakrabarti \[[@R35]\], Jeevathayaparan *et al*. \[[@R27]\]
  2\.                        Stimulation of peripheral and skeletal muscle glucose utilisation   Day *et al*. \[[@R19]\]); Bailey and Day \[[@R8]\], Cummings *et al*. \[[@R25]\]
  3\.                        Inhibition of intestinal glucose uptake                             Meir and Yaniv \[[@R47]\]; Ahmed *et al*. \[[@R33]\], Ahmed *et al*. \[[@R40]\]
  4\.                        Inhibition of hexokinase activity                                   Meir and Yaniv \[[@R47]\]
  5\.                        Suppression of key gluconeogenic enzymes                            Shibib *et al*. \[[@R48]\]
  6\.                        Stimulation of key enzyme of HMP pathway                            Shibib *et al*. \[[@R48]\]
  7\.                        Preservation of islet beta cells and their functions                Ahmed *et al*. \[[@R39]\]; Ahmed *et al*. \[[@R40]\]
